Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Massachusetts General Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb
Information provided by (Responsible Party):
Philip C. Amrein, M.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01173679
First received: July 28, 2010
Last updated: November 30, 2012
Last verified: November 2012
  Purpose

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death of CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells. The purpose of this study is to see of the study drug dasatinib, in combination with fludarabine and rituximab, is safe and effective to use for people with relapsed or refractory CLL/SLL.


Condition Intervention Phase
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Drug: dasatinib
Drug: Rituximab
Drug: fludarabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Response rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To describe the response rate of complete respone and partial response to treatment with this drug combination.


Secondary Outcome Measures:
  • Duration of Response [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To describe the duration of response

  • Progression-Free and Overall Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To describe the progression-free and overall surivial

  • Toxicities [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Dasatinib may enhance the myelosuppression expected from fludarabine. This toxicity will be monitored with frequent CBC's. If after Day 21 of a cycle there is a grade 4 cytopenia, a dose reduction will occur in the next cycle of treatment, and that cycle cannot start until the ANC > 1,000 and the platelets > 25,000. There is also a risk for pleural effusions with dasatinib, but the risk will be low, since there is a break from dasatinib dosing on days 15-28 of each cycle. Nevertheless, if a grade 2 pleural effusion occurs, there will be a dose reduction in the next cycle of treatment.


Estimated Enrollment: 27
Study Start Date: July 2010
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: dasatinib
    Taken orally once a day on days 1-14 of each 28-day cycle
    Drug: Rituximab
    Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
    Drug: fludarabine
    Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
Detailed Description:
  • Since the purpose of the study is to determine the response rate of the 3 drug regimen, everyone who participates will receive the same dose of the study drug, dasatinib and the 2 standard drugs, fludarabine and rituximab.
  • Participants will receive the drugs dasatinib, fludarabine, and rituximab at the following time points through each cycle of treatment. A cycle of study treatment is 28 days. Dasatinib pills will be taken orally each day for the first 2 weeks of each cycle. Fludarabine will be give intravenously on three days of each cycle (Days 3-5 in the first cycle, days 1-3 after that). Rituximab will be given intravenously with a total dose of 375 mg/m2 each cycle (split on Days 3+4 in the first cycle and at the discretion of the treating physician after that on Days 1-3).
  • The following procedures will be repeated throughout the study: medical history review; physical exam; performance status test; blood tests and EKG. They will occur daily during the first week of treatment, then weekly for the rest of cycle 1. After cycle 1 these procedures will be done once a week for 4 weeks then once a month for 6 months.
  • Tumor assessments will be repeated once every 2 months for the first six months of the study, and then once every 6 months after that.
  • Blood samples will be obtained in the first 5 days of treatment for pharmacokinetic studies and pharmacodynamic studies.
  • Participants that are benefiting from the study treatment after the first cycle can continue to receive an additional 6 cycles of study treatment.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CLL/SLL with cells positive by flow cytometry (or immunostaining) for CD19, CD23, and CD5. Patients may be CD23 negative as long as they are also cyclin D1 negative or t(11;14) negative.
  • Participants must have received at least 1 prior regimen containing a purine analogue or have received at least 2 chemotherapy regimens not containing a purine analogue. Patients may be refractory to single-agent purine analogue treatment, but patients may not be refractory to a combination of purine analogue with rituximab. Patients may have received rituximab.
  • 18 years of age or older
  • Able to take oral medications
  • ECOG Performance Status of 2 or better
  • Adequate organ function to tolerate chemotherapy
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration and agree to use and utilize an adequate method of contraception throughout treatment and for at least 4 weeks after study is stopped.
  • Require treatment based on 1996 NCI-WG criteria updated in 2008 by the IWCLL
  • Patient agrees to discontinue St. John's Wort while receiving dasatinib therapy and stop at least 5 days before starting dasatinib.
  • Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of dasatinib

Exclusion Criteria:

  • Pregnant or breastfeeding women
  • Uncontrolled angina, congestive heart failure, or MI within 6 months
  • Diagnosed or suspected congenital long QT syndrome
  • Any history of clinically significant ventricular arrhythmias
  • Prolonged QTc interval on pre-entry ECG
  • Uncontrolled hypertension
  • Hypokalemia or hypomagnesemia that is not corrected prior to dasatinib administration
  • Patients should not be taking drugs that are generally accepted to have a risk of causing Torsades de Pointes
  • Known HIV positive
  • Known significant bleeding disorder unrelated to CLL
  • Any significant pleural or pericardial effusion
  • Patients may not have another malignancy that is uncontrolled or requires treatment within a year of starting this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01173679

Contacts
Contact: Philip Amrein, MD 617-726-8748 pamrein@partners.org

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02115
Sub-Investigator: Jon Arnason, M.D.         
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb
Investigators
Principal Investigator: Philip Amrein, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Philip C. Amrein, M.D., Assistant Professor of Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01173679     History of Changes
Other Study ID Numbers: 09-325
Study First Received: July 28, 2010
Last Updated: November 30, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
CLL
fludarabine
rituximab
dasatinib
refractory
relapsed

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Lymphoma
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Dasatinib
Fludarabine
Fludarabine phosphate
Rituximab
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 19, 2014